Trial Profile
A Multi-Center, Open-Label Trial of the Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Mar 2018
Price :
$35
*
At a glance
- Drugs Velmanase alfa (Primary)
- Indications Alpha-Mannosidosis
- Focus Therapeutic Use
- Sponsors Zymenex A/S
- 04 May 2015 Accrual to date is 11% according to United Kingdom Clinical Research Network record.
- 09 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 20 May 2014 New trial record